INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10767006	
Filing Date		2004-01-30	
First Named Inventor Akira		по	
Art Unit		3682	
Examiner Name Thorr		nas R. Hannon	
Attorney Docket Number		ASAIN0138	

				Attorney Docket Number		ASAIN0138				
					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee or A of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	3276827		1966-1	0-04	B. Diver et al.				
If you wish	to a	d additional U.S. Pater	nt citatio	n inform	ation pl	ease click the A	Add button.		Add	
			U.S.P.	ATENT	APPLI	CATION PUBL	ICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date Name of Patentee or Applicant of cited Document		Releva	,Columns,Lines whe ant Passages or Rele s Appear			
	1									
If you wish	n to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information pl	ease click the Ad	d button	1. Add	
				FOREIG	SN PAT	ENT DOCUME	NTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	74
	1	1071855	GB			1967-06-14	Bristol Siddeley Er Limited	ngines		
	2	0391001	ЕP		A1	1990-10-10	General Motors Corporation			
If you wish	n to ac	dd additional Foreign Pa	atent Do	cument	citation	information ple	ease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DOG	UMENTS		Remove	

	Application Number		10767006	
INFORMATION DIGGS COURT	Filing Date		2004-01-30	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Akira		a ITO	
(Not for submission under 37 CFR 1.99)	Art Unit		3682	
(·,	Examiner Name Thorr		omas R. Hannon	
	Attorney Docket Numb	er	ASAIN0138	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5	
	1	European Search Report in corresponding application EP 04001990.3 completed December 20, 2005 and mailed January 17, 2006		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPT/D Patient Documents at year USPT(D,QQ/ or MEEP 801.04. ² Enter office that issued the document, by the bio-oblete code (WIPD Standard ST3.) ² Sort plaquence plants chouments, be excited not fine year of the Emperor most procedure the sent number of the period tocument.

* Kind of document by the opporpriate symbols as indicated on the document under WIPD Standard ST.18 if possible. ³ Applicant is to place a check mark here if English targuages breakfalors in attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10767006	
	Filing Date		2004-01-30	
First Named Inventor Akira		Akira	по	
	Art Unit		3682	
	Examiner Name	Thor	nas R. Hannon	
	Attorney Docket Number		ASAIN0138	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication \overline{Q} from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CPR 1,87/eQ(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

.loem-Live Szini

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

31799

Tomas or and origination			
Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2006-03-17

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Compartment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.